drugset / Trial / NCT03678480

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

NCT03678480

Phase 2 Withdrawn HighTide Biopharma Pty Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.

Timeline

Start
2021-03-01
Primary completion
2021-10-04
Completion
2021-11-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ursodeoxycholic Acid Small molecule 250 mg
Subject berberine ursodeoxycholate Small molecule 500 mg